Difference between revisions of "Part:BBa K3117023:Design"

 
Line 7: Line 7:
  
 
===Design Notes===
 
===Design Notes===
−
...
+
 
 +
This part was codon optimized for expression in mammalian cells.
  
  
Line 13: Line 14:
 
===Source===
 
===Source===
  
−
...
+
The sequence of this part origins from the patent (Bonvini et al., 2017)
  
 
===References===
 
===References===
 +
 +
[1]: Carreras-Sangrà, Nelson; Tomé-Amat, Jaime; García-Ortega, Lucía; Batt, Carl A.; Oñaderra, Mercedes; Martínez-del-Pozo, Alvaro et al. (2012): Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin. In: Protein engineering, design & selection : PEDS 25 (8), S. 425–435. DOI: 10.1093/protein/gzs032.
 +
 +
[2]: Bonvini, E., Moore, P. A., Li, J. C., Johnson, L. S., & Shah, K. (2017). U.S. Patent Application No. 15/313,765.

Revision as of 22:52, 21 October 2019


scFv VL against GPA33 codon optimized for CHO expression


Assembly Compatibility:
  • 10
    COMPATIBLE WITH RFC[10]
  • 12
    COMPATIBLE WITH RFC[12]
  • 21
    COMPATIBLE WITH RFC[21]
  • 23
    COMPATIBLE WITH RFC[23]
  • 25
    COMPATIBLE WITH RFC[25]
  • 1000
    COMPATIBLE WITH RFC[1000]


Design Notes

This part was codon optimized for expression in mammalian cells.


Source

The sequence of this part origins from the patent (Bonvini et al., 2017)

References

[1]: Carreras-Sangrà, Nelson; Tomé-Amat, Jaime; García-Ortega, Lucía; Batt, Carl A.; Oñaderra, Mercedes; Martínez-del-Pozo, Alvaro et al. (2012): Production and characterization of a colon cancer-specific immunotoxin based on the fungal ribotoxin α-sarcin. In: Protein engineering, design & selection : PEDS 25 (8), S. 425–435. DOI: 10.1093/protein/gzs032.

[2]: Bonvini, E., Moore, P. A., Li, J. C., Johnson, L. S., & Shah, K. (2017). U.S. Patent Application No. 15/313,765.